Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer and BioNTech received FDA approval for COMIRNATY®, making it the first FDA-approved COVID-19 vaccine for individuals aged 16 and older. This vaccine has been available under Emergency Use Authorization since December 2020. The approval validates the vaccine's efficacy and safety, supported by long-term Phase 3 trial data. Approximately 60% of eligible Americans are fully vaccinated, and the companies aim to enhance vaccine confidence. COMIRNATY is also authorized for individuals aged 12-15 under EUA and will seek further approvals for booster doses and younger age groups.
Pfizer (NYSE: PFE) has announced its definitive agreement to acquire Trillium Therapeutics (NASDAQ/TSX: TRIL) for an equity value of $2.26 billion, equating to $18.50 per share, marking a significant 118% premium. The acquisition aims to enhance Pfizer's oncology portfolio, especially in treating blood cancers, by integrating Trillium's lead molecules, TTI-622 and TTI-621, which target the SIRPα-CD47 axis. These molecules are in advanced clinical trials and show promise as therapies for various hematological malignancies.
Pfizer Inc. (NYSE: PFE) has received approval from the European Commission for XELJANZ® (tofacitinib) for treating active polyarticular juvenile idiopathic arthritis (JIA) and juvenile psoriatic arthritis (PsA) in patients aged two years and older who have not responded adequately to previous disease-modifying antirheumatic drug (DMARD) therapies. The approval includes a new oral solution and a once-daily tablet formulation. XELJANZ is the first JAK inhibitor approved in Europe for these indications and has been studied across over 50 clinical trials globally.
Summary not available.
Pfizer (PFE) and BioNTech (BNTX) have submitted Phase 1 data to the FDA for a booster dose of their COVID-19 vaccine (BNT162b2). This submission follows successful Phase 1 trials showing significantly higher neutralizing antibodies after a third dose compared to the two-dose schedule. The companies plan to also submit this data to the EMA and other authorities soon. Although the booster is not yet widely authorized in the U.S., it was recently approved for immunocompromised individuals. Further Phase 3 results are expected shortly.
Pfizer Inc. (NYSE:PFE) has received FDA approval for TICOVAC™, a vaccine for tick-borne encephalitis (TBE), aimed at individuals aged 1 and older. This makes TICOVAC™ the first FDA-approved vaccine to protect U.S. residents traveling to TBE-endemic areas. With over 170 million doses distributed globally over the past 45 years, the vaccine shows a seropositivity rate of 99.5% in children and 98.7-100% in adults after three doses. While TBE is not endemic in the U.S., it poses significant health risks in over 35 countries worldwide.
Pfizer Inc. (NYSE: PFE) announced positive top-line results from the Phase 2b/3 ALLEGRO trial for ritlecitinib, an oral treatment for alopecia areata. The study met its primary endpoint, showing significant scalp hair regrowth in patients with at least 50% hair loss. Ritlecitinib’s safety profile was consistent with earlier studies, with common adverse events including nasopharyngitis and headache. There were no major adverse cardiac events reported. Full study results will be published, supporting future regulatory filings.
Pfizer Inc. (NYSE: PFE) reported a substantial 92% revenue increase in Q2 2021, totaling $18.98 billion, attributed to strong sales of its COVID-19 vaccine, BNT162b2, which alone contributed $7.8 billion. The company raised its 2021 financial guidance, now expecting revenues of $78.0 to $80.0 billion. Adjusted diluted EPS is projected between $3.95 and $4.05, reflecting a 77% increase from 2020. The company also reported a 10% operational growth in its business excluding the vaccine. Pfizer aims for a 6% CAGR through 2025, buoyed by promising clinical pipelines and revenue forecasts.
Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) announced the U.S. government's purchase of an additional 200 million doses of their COVID-19 vaccine. This increases the total to 500 million doses under their supply agreement. The companies plan to deliver 110 million doses by December 31, 2021, and the remaining doses by April 30, 2022. The U.S. government will continue to provide the vaccine for free. The vaccine remains under Emergency Use Authorization and is aimed at preventing COVID-19.
Pfizer (NYSE: PFE) announced the FDA will not meet the PDUFA goal dates for its New Drug Application for abrocitinib, aimed at treating moderate to severe atopic dermatitis, and the supplemental application for XELJANZ/XELJANZ XR (tofacitinib) for active ankylosing spondylitis. The delay is attributed to the FDA's ongoing review of Pfizer's post-marketing safety study for tofacitinib in rheumatoid arthritis. Pfizer remains confident in the benefit-risk profiles of both drugs.